Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
- Marzena Ciechomska,
- Krzysztof Bonek,
- Michal Merdas,
- Patryk Zarecki,
- Jerzy Swierkot,
- Piotr Gluszko,
- Katarzyna Bogunia-Kubik,
- Wlodzimierz Maslinski
Arch Immunol Ther Exp (Warsz) 2018 May 9. Epub 2018 May 9.
Department of Pathophysiology and Immunology, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland.
In this study, we analysed the expression level of sera circulating miRNA-5196 in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients before and after tumor necrosis factor (TNF)-α therapy as biomarkers predicting positive treatment outcome. We enrolled 10 RA patients, 13 AS patients, and 12 healthy individuals in the study. The expression of miRNA-5196 was measured by real-time polymerase chain reaction before and after anti-TNF-α therapy. Read More